Financing the industrial chemicals & polymers chain
A pharma or FMCG corporate places orders on a chemical / polymer processor, who buys price-volatile raw materials on spot-cash while the buyer settles on rigid 90-day terms. The Risk Signals Pack verifies the parties and the trade so a lender can fund the receivable with the risks surfaced.
Cluster intelligence · FY24
~$18 Bn
chemical & polymer exports (CHEMEXCIL + PLEXCONCIL segments)
6,000+
MSME chemical processors in Gujarat / Maharashtra belt
Oct – Mar
pharma / FMCG anchor procurement cycle
₹20L – ₹2Cr
processor receivable / supply ticket range
Top export buyer markets:
USA~17%China~13%Netherlands~9%Source: CHEMEXCIL · PLEXCONCIL Annual Report FY24. Figures are sector-level context from public export-promotion council reports — not AssureLocker data. For indicative context only; deal volumes vary by borrower and lender.
The three-party chain
Registration status, name match, and an established trade relationship with the processor
Identity verified, GST filing trail, bank-cashflow (consent-based, via the lender), no undisclosed charge or prior assignment on the receivable
Capacity (turnover) for the volume, GST corroboration, related-party distance from A and B
What the pack catches in a chemicals trade
- A receivable already assigned or charged elsewhere — surfaced from the CERSAI search (lender-side) before disbursal.
- A feedstock “supplier” that shares directors or an address with the processor (related-party inflation).
- A processor without the turnover or capacity for the order volume.
- An invoice leg with no e-way / GST movement corroborating the goods actually moved.
- An invoice value that diverges sharply from feedstock / market norms — price-volatility flagged for the lender to weigh.
Schemes & evidence in chemicals
Most chemicalsMSMEs aren’t rejected because the business is weak — they’re bounced on fixable, technical gaps. The programmes below de-risk this lending, and each one (and the lender behind it) looks for specific evidence. Our pack assembles that evidence — source-verified and tier-labelled — so a creditworthy deal reads clearly. Signals, not decisions — the lender decides.
Programmes that de-risk it
- CGTMSE — collateral-free guarantee for chemical/polymer/packaging MSMEs
- TReDS — on-exchange discounting of accepted buyer invoices
Evidence our pack assembles
- ✓ Buyer PO + accepted-receivable confirmation
- ✓ e-way / movement consistency (incl. hazmat handling)
- ✓ Concentration to the buyer / counterparty
- + GSTIN status + filing regularity
- + e-invoice (IRN) & e-way consistency
- + Buyer PO / acceptance
- + Prior-charge / double-financing signal (lender-run on CERSAI)
- + Account Aggregator cash-flow (lender-side)
Scheme names are referenced for context only — see the avoidable rejections that bounce good MSMEs. AssureLocker is not affiliated with, integrated into, or endorsed by any government scheme; eligibility and approval rest with the lender and the scheme.
See a chemicals-trade pack
Flip between a clean, an incomplete and an adverse deal — then talk to us about an anchor-led pilot.
Evidence and signals for the lender’s decision only — not a credit score, and not a guarantee. Registry and bank-cashflow checks run under the lender’s own access and consent. Illustrative example.
What this is — and isn’t
Not TReDS
We don't run an exchange or auction — we assemble evidence for off-exchange / bilateral deals, complementary to TReDS.
Not CERSAI
We don't operate the charge registry; the charge search is lender-run on the lender's own CERSAI access (via AssureConnect).
Not an Account Aggregator
We're not an AA / FIU; AA cashflow is consent-pulled on the lender's own FIU — aggregates only.
Not an LMS
We don't book loans, set advance rates or disburse; we hand a review-ready packet to the lender's system of record.
Pilot ask
We’re looking for 3–5 lenders, anchors or associations to test this use case on controlled sample deals. No lending, broking, fund custody or credit decisioning by AssureLocker.
Success criteria: time-to-evidence in hours not days · risks (duplicate-financing, related-party, capacity) surfaced earlier · analyst hours saved per deal · an audit-ready, evidence-tiered trail.